BioDiem, Merck deal

BioDiem regained from Merck's Nobilon International B.V. unit worldwide rights, excluding Russia and the Commonwealth of Independent States (CIS), to BioDiem's live attenuated influenza vaccine (LAIV) technology.

Read the full 275 word article

How to gain access

Continue reading with a
two-week free trial.